Developing Innovative Cancer Immunotherapies

Learn about our pipeline

Clinical Trials
Recruiting

Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!
Growth

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more

Press Releases
Recent News

view all

MEDIA

Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading

PIPELINE

Program1

Indication

Discovery

Preclinical

Phase 1 Safety
Dose-Escalation

Phase 1b
Dose-Expansion/
Efficacy Signal

AB928 (Dual Adenosine Receptor Antagonist) LEARN MORE

AB928 + AB122 (anti-PD-1)

CRPC, RCC

Title

88%

AB928 + AB122 + Carbo/Pem

NSCLC

Title

65%

AB928 + mFOLFOX

CRC

Title

88%

AB928 + PLD2

TNBC

Title

88%

AB928 + PLD2 + IPI-5493

TNBC

Title

65%

AB680 (Small Molecule CD73 Inhibitor) LEARN MORE

AB680 + AB122 + Gem/nab-paclitaxel

Pancreatic

Title

65%

AB122 (Anti-PD-1 Antibody) LEARN MORE

AB122 monotherapy

Biomarker-selected
(tumor-type agnostic)

Title

88%

AB154 (Anti-TIGIT Antibody) LEARN MORE

AB154 + AB122

Solid Tumors

Title

65%

Discovery and Preclinical Small Molecules

AB610 (PI3Kγ Inhibitor)

Oncology Indications

Title

22%

HIF-2α Antagonist

Oncology Indications

Title

18%

Axl Inhibitor

Oncology Indications

Title

13%

PAK4 Inhibitor

Oncology Indications

Title

13%
  1. Taiho has an option to Arcus’s programs in Japan and certain other Asian territories (excluding China) over a 5-year term.
  2. Pegylated liposomal doxorubicin.
  3. Clinical collaboration with Infinity Pharmaceuticals (IPI-549).

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership